Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 12/20 | 0.94 |
| ▸ | SLC6A5 | Q9Y345 | 11/20 | 0.94 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.70 |
| ▸ | MEN1 | O00255 | 2/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.68 |
| ▸ | MAPT | P10636 | 2/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | POLB | P06746 | 1/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.68 |
| ▸ | HPGD | P15428 | 1/20 | 0.64 |
| ▸ | THRB | P10828 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3921674 | 0.98 | SLC6A5 (0.98) | SLC6A9SLC6A5ALDH1A1MEN1KMT2A | |
| SCHEMBL1689566 | 0.97 | SLC6A5 (1.00) | SLC6A9SLC6A5ALDH1A1MEN1KMT2A | |
| SCHEMBL3917801 | 0.97 | SLC6A5 (1.00) | SLC6A9SLC6A5ALDH1A1MEN1KMT2A | |
| SCHEMBL13687954 | 0.93 | SLC6A9 (0.85) | SLC6A9SLC6A5ALDH1A1MEN1KMT2A | |
| SCHEMBL3923755 | 0.93 | SLC6A9 (0.85) | SLC6A9SLC6A5ALDH1A1MEN1KMT2A | |
| SCHEMBL3927563 | 0.92 | SLC6A5 (0.85) | SLC6A9SLC6A5ALDH1A1MEN1KMT2A | |
| SCHEMBL3917370 | 0.91 | SLC6A9 (1.00) | SLC6A9SLC6A5 | |
| SCHEMBL3924828 | 0.91 | SLC6A9 (0.82) | SLC6A9SLC6A5ALDH1A1MEN1KMT2A | |
| SCHEMBL3929006 | 0.90 | SLC6A5 (0.81) | SLC6A9SLC6A5ALDH1A1MEN1KMT2A | |
| SCHEMBL5048691 | 0.90 | SLC6A9 (0.81) | SLC6A9SLC6A5ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7595314-B2 | Benzoyl-piperazine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-09-29 | — | — | US | disclosed |
| US-20090192136-A1 | BENZOYL-PIPERAZINE DERIVATIVES | ALBERATI-GIANI DANIELA | 2009-07-30 | — | — | US | disclosed |
| US-7427612-B2 | Benzoyl-piperazine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-09-23 | — | — | US | disclosed |
| US-7427612-B2 | Benzoyl-piperazine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192136-A1 | BENZOYL-PIPERAZINE DERIVATIVES | OPRL1, ACHE, PNMT | SLC6A9 4305/4885SLC6A5 2174/4885ALDH1A1 582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.